FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis

Kouwen, M.C.A. van; Jansen, J. B. M. J.; Goor, Harry van; Castro, Steve de; Oyen, Wim J.G.; Drenth, Joost P.H.

doi:10.1007/s00259-004-1689-4

Cited by 95 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 F-FDG PET is also affected by other metabolic conditions such as altered glucose metabolism, causing a decreased sensitivity for detection of pancreatic cancer in patients with elevated plasma glucose levels (22,23). 18 F-FDG PET may also be inferior to MRI or spiral CT for detecting pancreatic cancer but is more accurate for detecting distant metastases (24)(25)(26)(27). In a study by Heinrich et al, the sensitivity of combined 18 F-FDG PET/CT for detecting locoregional lymph node metastases was as low as 22%.…”

Section: Discussionmentioning

confidence: 99%

“…This has led to a cost reduction of $63,000, indicating that the use of 18 F-FDG PET/CT may be cost-efficient despite the mentioned shortcomings (24). Even in the presence of inflammatory disease, 18 F-FDG PET may be helpful in detecting pancreatic cancer in patients with CP (27). However, the patient numbers are small, and the clinical role of PET for managing undefined pancreatic tumors or staging pancreatic cancer remains to be determined.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors

Herrmann

Eckel²,

Schmidt³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors

Herrmann

Eckel²,

Schmidt³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

“…This was possibly due to the histology of the cancer being a moderately differentiated adenocarcinoma. Prior authors have described the potential utility and pitfalls of characterizing primary pancreatic cancer using FDG PET [9,10] describing mixed success in various clinical scenarios. The highly selected patient population in this study precludes any analysis of the ability of FDG PET to detect, characterize, and stage pancreatic adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Quon

Chang

Chin

et al. 2007

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose-The aim of this study was to evaluate the potential of 18 F-fluorothymidine (FLT) PET/CT for imaging pancreatic adenocarcinoma. Methods-This was a pilot study of five patients (four males, one female) with newly diagnosed and previously untreated pancreatic adenocarcinoma. Patients underwent FLT PET/CT, 18 Ffluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced CT scanning before treatment. The presence of cancer was confirmed by histopathological analysis at the time of scanning in all five patients. The degree of FLT and FDG uptake at the primary tumor site was assessed using visual interpretation and semi-quantitative SUV analyses.Results-The primary tumor size ranged from 2.5×2.8 cm to 3.5×7.0 cm. The SUV of FLT uptake within the primary tumor ranged from 2.1 to 3.1. Using visual interpretation, the primary cancer could be detected from background activity in two of five patients (40%) on FLT PET/CT. By comparison, FDG uptake was higher in each patient with a SUV range of 3.4 to 10.8, and the primary cancer could be detected from background in all five patients (100%).Conclusions-In this pilot study of five patients with primary pancreatic adenocarcinoma, FLT PET/CT scanning showed poor lesion detectability and relatively low levels of radiotracer uptake in the primary tumor.

show abstract

“…Current image and laboratory tests have improved the diagnostic efficiency to some extent, but insufficiently. Recently, fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer, and is reported to be a valuable diagnostic modality for differentiating malignant from benign lesions of the pancreas 1,2,3,4,5,6,7 . Therefore, many patients who are suspected of having pancreatic cancer tend to undergo FDG-PET, which is necessary to differentiate between pancreatic cancer and benign pancreatic conditions such as tumor-forming chronic pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography

et al. 2008

View full text Add to dashboard Cite

Purposes: Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer. Because autoimmune pancreatitis is easily misdiagnosed as pancreatic cancer and can be tested for by FDG-PET analysis based on the presence of suspected pancreatic cancer, we attempted to clarify the differences in FDG-PET findings between the two conditions. Methods: We compared the FDG-PET findings between 15 patients with autoimmune pancreatitis and 26 patients with pancreatic cancer. The findings were evaluated visually or semiquantitatively using the maximum standardized uptake value and the accumulation pattern of FDG. Results: FDG uptake was found in all 15 patients with autoimmune pancreatitis, whereas it was found in 19 of 26 patients (73.1%) with pancreatic cancer. The accumulation pattern of nodular shape was frequently seen in pancreatic cancer with significance, whereas a longitudinal shape indicated the existence of autoimmune pancreatitis. Heterogeneous accumulation was found in almost all cases of autoimmune pancreatitis, whereas homogeneous accumulation was found in pancreatic cancer. Most cases of pancreatic cancer showed solitary localization with significant difference, whereas multiple localizations in the pancreas favored the existence of autoimmune pancreatitis. FDG uptakes in the hilar lymph node were more frequently seen in autoimmune pancreatitis than in pancreatic cancer with significance, and those in the lachrymal gland, salivary gland, biliary duct, retroperitoneal space, and prostate were only seen in autoimmune pancreatitis. Conclusions: FDG-PET provides a useful tool for differentiating autoimmune pancreatitis from suspected pancreatic cancer, if its accumulation pattern and extra-pancreatic involvements are considered. IgG4 measurement and other current image tests will confirm further diagnosis.

show abstract

FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis

Abstract: These data suggest that FDG-PET has a potential role as a diagnostic tool for detecting CA in longstanding CP.

Cited by 95 publications

References 31 publications

In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors

In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography

Contact Info

Product

Resources

About